title: G-CSF alone mobilizes sufficient peripheral blood CD34+ cells for positive selection in newly diagnosed patients with myeloma.
abstract: We have evaluated CD34+ cell positive selection from granulocyte-colony stimulating factor (G-CSF)-mobilized peripheral blood progenitor cells (PBPC) in 26 patients with either multiple myeloma (MM, n = 18) or follicular non-Hodgkin's lymphoma (NHL, n = 8). 26 PBPC were collected with two leukaphereses: 16 contained sufficient numbers of CD34+ cells and were elected. The absolute number of CD34+ cells in the leukapheresis products was found to be significantly related to the duration of underlying disease and exposure to prior treatment. CD34+ cell positive selection allowed recovery of a median of 35% of CD34+ cells, the selected fraction containing a median number of 1.43 x 10(6)/kg CD34+ cells/kg (range 0.48-41.5). 10 patients were transplanted and received a median dose of 1.51 x 10(6) CD34+ cells (range 0.48-4.2). The median time to granulocyte ( > 0.5 x 10(9)/l) and platelet ( > 20 x 10(9)/l) engraftment was 12 and 13 d respectively (ranges 10-13 and 0-95). Lymphoma cells were found by a sensitive polymerase chain reaction technique in four out of five CD34+ cell fractions tested.
authors.affiliation: Laboratoire d'Hématologie, Hotel Dieu, Nantes, France.
authors.forename: B
authors.initials: B
authors.lastname: Mahé
authors.forename: N
authors.initials: N
authors.lastname: Milpied
authors.forename: S
authors.initials: S
authors.lastname: Hermouet
authors.forename: N
authors.initials: N
authors.lastname: Robillard
authors.forename: P
authors.initials: P
authors.lastname: Moreau
authors.forename: S
authors.initials: S
authors.lastname: Letortorec
authors.forename: M J
authors.initials: MJ
authors.lastname: Rapp
authors.forename: R
authors.initials: R
authors.lastname: Bataille
authors.forename: J L
authors.initials: JL
authors.lastname: Harousseau
mesh_terms: D000328:Adult; D000368:Aged; D018952:Antigens, CD34 / Q000032:analysis*; D002469:Cell Separation / Q000379:methods*; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology*; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000187:drug effects / Q000276:immunology*; D006801:Humans; D007937:Leukapheresis; D008224:Lymphoma, Follicular / Q000532:radiotherapy / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000532:radiotherapy / Q000628:therapy*; D016133:Polymerase Chain Reaction; D011518:Proto-Oncogene Proteins / Q000032:analysis; D019253:Proto-Oncogene Proteins c-bcl-2; D014184:Transplantation, Homologous; D014410:Tumor Stem Cell Assay; D014916:Whole-Body Irradiation
chemical_list: D018952:Antigens, CD34; D011518:Proto-Oncogene Proteins; D019253:Proto-Oncogene Proteins c-bcl-2; D016179:Granulocyte Colony-Stimulating Factor